Initial triple combination therapy including sotatercept in a patient with severe idiopathic pulmonary arterial hypertension: a case report

Extract For patients with newly diagnosed idiopathic pulmonary arterial hypertension (IPAH) at high risk of death, current guidelines recommend initial triple combination therapy consisting of an endothelin receptor antagonist (ERA), a phosphodiesterase-5 inhibitor (PDE5i), and a parenteral prostacyclin analogue 1.